Literature DB >> 24911990

Novel role of Cdc42 and RalA GTPases in TNF-α mediated secretion of CCL2.

Kelly A Langert1, Cynthia L Pervan1, Evan B Stubbs1.   

Abstract

Transendothelial migration of autoreactive leukocytes into peripheral nerves is an early pathological hallmark of acute inflammatory demyelinating polyneuropathy (AIDP), a North American and European variant of Guillain-Barré Syndrome. Whereas the clinical management of AIDP is currently limited to non-selective immune modulating therapies, recent experimental studies support selective targeting of leukocyte trafficking as a promising alternative therapeutic strategy. Here, using a combination of targeted siRNA knockdown and pharmacological inhibitors, we report a novel role of both Cdc42 and RalA GTPases in facilitating TNF-α mediated CCL2 trafficking and release from immortalized rat peripheral nerve microvascular endoneurial endothelial cells. These findings raise interest in Cdc42 and RalA GTPases as potential therapeutic targets for the management of autoimmune inflammatory peripheral nerve disease.

Entities:  

Keywords:  Cdc42; GTPase; RalA; endothelial; siRNA

Mesh:

Substances:

Year:  2014        PMID: 24911990      PMCID: PMC4205150          DOI: 10.4161/sgtp.29260

Source DB:  PubMed          Journal:  Small GTPases        ISSN: 2154-1248


  38 in total

1.  Cdc42 GTPases facilitate TNF-α-mediated secretion of CCL2 from peripheral nerve microvascular endoneurial endothelial cells.

Authors:  Kelly A Langert; Cynthia L Von Zee; Evan B Stubbs
Journal:  J Peripher Nerv Syst       Date:  2013-09       Impact factor: 3.494

Review 2.  Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations.

Authors:  Carlos H Rojas-Fernandez; Jean-Christy F Cameron
Journal:  Ann Pharmacother       Date:  2012-04-03       Impact factor: 3.154

3.  Small GTP-binding protein Ral modulates regulated exocytosis of von Willebrand factor by endothelial cells.

Authors:  H P de Leeuw; M Fernandez-Borja; E A Reits; T Romani de Wit; P M Wijers-Koster; P L Hordijk; J Neefjes; J A van Mourik; J Voorberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-06       Impact factor: 8.311

4.  Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC.

Authors:  S Takeuchi; S Kawashima; Y Rikitake; T Ueyama; N Inoue; K Hirata; M Yokoyama
Journal:  Biochem Biophys Res Commun       Date:  2000-03-05       Impact factor: 3.575

Review 5.  Statins and the risk of new-onset diabetes: a review of recent evidence.

Authors:  David Preiss; Naveed Sattar
Journal:  Curr Opin Lipidol       Date:  2011-12       Impact factor: 4.776

6.  HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells.

Authors:  Takayuki Ito; Uichi Ikeda; Masahisa Shimpo; Ruri Ohki; Masafumi Takahashi; Keiji Yamamoto; Kazuyuki Shimada
Journal:  Cardiovasc Drugs Ther       Date:  2002-03       Impact factor: 3.727

Review 7.  Cell motility: can Rho GTPases and microtubules point the way?

Authors:  T Wittmann; C M Waterman-Storer
Journal:  J Cell Sci       Date:  2001-11       Impact factor: 5.285

8.  Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis.

Authors:  John Greenwood; Peter Adamson; Claire E Walters; Gareth Pryce; Deborah J R Hankey; Said M Sebti; Andrew D Hamilton; David Baker
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

9.  Tumour necrosis factor α enhances CCL2 and ICAM-1 expression in peripheral nerve microvascular endoneurial endothelial cells.

Authors:  Kelly A Langert; Cynthia L Von Zee; Evan B Stubbs
Journal:  ASN Neuro       Date:  2013-02-06       Impact factor: 4.146

10.  Inhibition of Rho and Rac geranylgeranylation by atorvastatin is critical for preservation of endothelial junction integrity.

Authors:  Hongbing Xiao; Xiong Qin; Ding Ping; Keqiang Zuo
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

View more
  7 in total

Review 1.  Targeting the blood-nerve barrier for the management of immune-mediated peripheral neuropathies.

Authors:  Evan B Stubbs
Journal:  Exp Neurol       Date:  2020-06-17       Impact factor: 5.330

2.  Attenuation of experimental autoimmune neuritis with locally administered lovastatin-encapsulating poly(lactic-co-glycolic) acid nanoparticles.

Authors:  Kelly A Langert; Bruktawit Goshu; Evan B Stubbs
Journal:  J Neurochem       Date:  2016-12-20       Impact factor: 5.372

3.  A Protumorigenic mDia2-MIRO1 Axis Controls Mitochondrial Positioning and Function in Cancer-Associated Fibroblasts.

Authors:  Michael Cangkrama; Huan Liu; James Whipman; Maria Zubair; Mai Matsushita; Michela Di Filippo; Manfred Kopf; Metello Innocenti; Sabine Werner
Journal:  Cancer Res       Date:  2022-10-17       Impact factor: 13.312

4.  Rho GTPase signaling promotes constitutive expression and release of TGF-β2 by human trabecular meshwork cells.

Authors:  Cynthia L Pervan; Jonathan D Lautz; Andrea L Blitzer; Kelly A Langert; Evan B Stubbs
Journal:  Exp Eye Res       Date:  2015-12-30       Impact factor: 3.467

Review 5.  Novel pathomechanisms in inflammatory neuropathies.

Authors:  David Schafflick; Bernd C Kieseier; Heinz Wiendl; Gerd Meyer Zu Horste
Journal:  J Neuroinflammation       Date:  2017-11-28       Impact factor: 8.322

6.  TGF-β2 Promotes Oxidative Stress in Human Trabecular Meshwork Cells by Selectively Enhancing NADPH Oxidase 4 Expression.

Authors:  Vidhya R Rao; Evan B Stubbs
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-04-01       Impact factor: 4.925

7.  Non-muscular myosin light chain kinase triggers intermittent hypoxia-induced interleukin-6 release, endothelial dysfunction and permeability.

Authors:  Sylvain Recoquillon; Manuel Gómez-Guzmán; Marion Rodier; Camille Koffi; Mathieu Nitiéma; Frédéric Gagnadoux; M Carmen Martínez; Ramaroson Andriantsitohaina
Journal:  Sci Rep       Date:  2017-10-20       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.